Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neukopathies

Steven Vernino, Phillip Anson Low, Robert D. Fealey, John D. Stewart, Gianrico Farrugia, Vanda A Lennon

Research output: Contribution to journalArticle

472 Citations (Scopus)

Abstract

Background: Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. Methods: We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Results: Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Conclusions: Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy. (C) 2000, Massachusetts Medical Society.

Original languageEnglish (US)
Pages (from-to)847-855
Number of pages9
JournalNew England Journal of Medicine
Volume343
Issue number12
DOIs
StatePublished - Sep 21 2000

Fingerprint

Cholinergic Receptors
Autoantibodies
Antibodies
Paraneoplastic Polyneuropathy
Primary Dysautonomias
epibatidine
Tonic Pupil
Postural Orthostatic Tachycardia Syndrome
Autonomic Ganglia
Blocking Antibodies
Diabetic Neuropathies
Medical Societies
Nicotinic Receptors
Neuroblastoma
Immunoprecipitation
Iodine
Lung Neoplasms
Serum
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neukopathies. / Vernino, Steven; Low, Phillip Anson; Fealey, Robert D.; Stewart, John D.; Farrugia, Gianrico; Lennon, Vanda A.

In: New England Journal of Medicine, Vol. 343, No. 12, 21.09.2000, p. 847-855.

Research output: Contribution to journalArticle

@article{4b84bb9dbfc340bdb58b1accea21a420,
title = "Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neukopathies",
abstract = "Background: Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. Methods: We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Results: Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Conclusions: Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy. (C) 2000, Massachusetts Medical Society.",
author = "Steven Vernino and Low, {Phillip Anson} and Fealey, {Robert D.} and Stewart, {John D.} and Gianrico Farrugia and Lennon, {Vanda A}",
year = "2000",
month = "9",
day = "21",
doi = "10.1056/NEJM200009213431204",
language = "English (US)",
volume = "343",
pages = "847--855",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "12",

}

TY - JOUR

T1 - Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neukopathies

AU - Vernino, Steven

AU - Low, Phillip Anson

AU - Fealey, Robert D.

AU - Stewart, John D.

AU - Farrugia, Gianrico

AU - Lennon, Vanda A

PY - 2000/9/21

Y1 - 2000/9/21

N2 - Background: Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. Methods: We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Results: Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Conclusions: Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy. (C) 2000, Massachusetts Medical Society.

AB - Background: Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. Methods: We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Results: Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Conclusions: Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy. (C) 2000, Massachusetts Medical Society.

UR - http://www.scopus.com/inward/record.url?scp=0034699650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034699650&partnerID=8YFLogxK

U2 - 10.1056/NEJM200009213431204

DO - 10.1056/NEJM200009213431204

M3 - Article

C2 - 10995864

AN - SCOPUS:0034699650

VL - 343

SP - 847

EP - 855

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 12

ER -